Simultaneous pancreas-kidney transplantation for end-stage renal failure in type 1 diabetes mellitus: Current perspectives.

Lakshmi Nagendra, Cornelius James Fernandez, Joseph M Pappachan
{"title":"Simultaneous pancreas-kidney transplantation for end-stage renal failure in type 1 diabetes mellitus: Current perspectives.","authors":"Lakshmi Nagendra,&nbsp;Cornelius James Fernandez,&nbsp;Joseph M Pappachan","doi":"10.5500/wjt.v13.i5.208","DOIUrl":null,"url":null,"abstract":"<p><p>Type 1 diabetes mellitus (T1DM) is one of the important causes of chronic kidney disease (CKD) and end-stage renal failure (ESRF). Even with the best available treatment options, management of T1DM poses significant challenges for cli nicians across the world, especially when associated with CKD and ESRF. Substantial increases in morbidity and mortality along with marked rise in treatment costs and marked reduction of quality of life are the usual consequences of onset of CKD and progression to ESRF in patients with T1DM. Simultaneous pancreas-kidney transplant (SPK) is an attractive and promising treatment option for patients with advanced CKD/ESRF and T1DM for potential cure of these diseases and possibly several complications. However, limited availability of the organs for transplantation, the need for long-term immunosuppression to prevent rejection, peri- and post-operative complications of SPK, lack of resources and the expertise for the procedure in many centers, and the cost implications related to the surgery and postoperative care of these patients are major issues faced by clinicians across the globe. This clinical update review compiles the latest evidence and current recommendations of SPK for patients with T1DM and advanced CKD/ESRF to enable clinicians to care for these diseases.</p>","PeriodicalId":68893,"journal":{"name":"世界移植杂志(英文版)","volume":"13 5","pages":"208-220"},"PeriodicalIF":0.0000,"publicationDate":"2023-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/eb/00/WJT-13-208.PMC10514751.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"世界移植杂志(英文版)","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5500/wjt.v13.i5.208","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Type 1 diabetes mellitus (T1DM) is one of the important causes of chronic kidney disease (CKD) and end-stage renal failure (ESRF). Even with the best available treatment options, management of T1DM poses significant challenges for cli nicians across the world, especially when associated with CKD and ESRF. Substantial increases in morbidity and mortality along with marked rise in treatment costs and marked reduction of quality of life are the usual consequences of onset of CKD and progression to ESRF in patients with T1DM. Simultaneous pancreas-kidney transplant (SPK) is an attractive and promising treatment option for patients with advanced CKD/ESRF and T1DM for potential cure of these diseases and possibly several complications. However, limited availability of the organs for transplantation, the need for long-term immunosuppression to prevent rejection, peri- and post-operative complications of SPK, lack of resources and the expertise for the procedure in many centers, and the cost implications related to the surgery and postoperative care of these patients are major issues faced by clinicians across the globe. This clinical update review compiles the latest evidence and current recommendations of SPK for patients with T1DM and advanced CKD/ESRF to enable clinicians to care for these diseases.

Abstract Image

Abstract Image

Abstract Image

胰肾联合移植治疗1型糖尿病终末期肾功能衰竭:当前观点。
1型糖尿病(T1DM)是慢性肾脏病(CKD)和终末期肾功能衰竭(ESRF)的重要病因之一。即使有最好的治疗选择,T1DM的管理也给世界各地的临床医生带来了重大挑战,尤其是当与CKD和ESRF相关时。发病率和死亡率的显著增加以及治疗费用的显著增加和生活质量的显著降低是T1DM患者CKD发病和进展为ESRF的常见后果。胰肾联合移植(SPK)是晚期CKD/ESRF和T1DM患者的一种有吸引力和前景的治疗选择,有可能治愈这些疾病和可能的几种并发症。然而,用于移植的器官有限,需要长期免疫抑制来预防排斥反应,SPK的围术期和术后并发症,许多中心缺乏资源和专业知识,以及与这些患者的手术和术后护理相关的成本影响,都是全球临床医生面临的主要问题。本临床更新综述汇集了针对T1DM和晚期CKD/ESRF患者的SPK的最新证据和当前建议,使临床医生能够护理这些疾病。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
364
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信